HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benzocaine studies

This article was originally published in The Tan Sheet

Executive Summary

CHPA's Oral Discomfort Task Group requests FDA meeting by end of April to "facilitate development of a mutually agreeable approach to studying clinically the benefits and use patterns of benzocaine," trade association says in March 22 letter to agency. CHPA will provide FDA with a background document two weeks before meeting containing rationale for the proposed study designs, responses to agency concerns about protocol. CHPA request responds to FDA's Jan. 8 letter, in which agency questioned proposed protocol for testing efficacy of benzocaine and eugenol for toothache relief (1"The Tan Sheet" Jan. 21, 2002, p. 5). Eugenol-related issues "will be addressed separately," CHPA says...

You may also be interested in...



Eugenol Inclusion In Oral Pain Monograph Requires Actual Use Data – FDA

Both a clinical safety trial and an actual use study are necessary to support including eugenol in the oral discomfort (relief) products final monograph, FDA tells the Consumer Healthcare Products Association

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

Topics

UsernamePublicRestriction

Register

RS130119

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel